Orthocell receives ethics approval for collagen scaffold study
04 May, 2016Orthocell has been granted ethical approval by St Vincent's Hospital Melbourne for a clinical study using its Celgro SMRT Grant collagen scaffold.
Clinical trials facility opens in Adelaide
02 May, 2016Pharmaceutical company IDT Australia has officially opened CMAX Adelaide, claimed to be Australia's largest and most contemporary early-phase clinical trial facility.
AusMedtech is coming to Adelaide
28 April, 2016Australian medical technology conference AusMedtech is coming to the Adelaide Convention and Exhibition Centre from 10–11 May.
Wet AMD trial meets primary safety objective
26 April, 2016Opthea has met the primary objective of safety in the dose escalation of its ongoing first-in-human clinical trial of OPT-302, a therapy for wet age-related macular degeneration (wet AMD) — the leading cause of blindness in the Western world.
CSL marks centenary with $25 million fellowship program
26 April, 2016Biotechnology company CSL observed a significant milestone on 25 April — 100 years of operation. As part of its birthday celebrations, the company is creating a flagship $25 million fellowship program for early-stage and translational research in Australia.
Dimerix to continue supplying propagermanium to kidney disease patients
20 April, 2016The TGA's special access scheme has granted Dimerix the right to continue supplying propagermanium to participants in its DMX-200 clinical trial, upon clinician approval and participant agreement.
3D-printed sleep apnoea device cleared by FDA
08 April, 2016Oventus Medical has received clearance from the US FDA for the O2VENT device, an oral appliance intended to reduce or alleviate snoring and mild to moderate obstructive sleep apnoea.
Prolonged survival in graft-versus-host disease study
07 April, 2016Cynata Therapeutics has announced positive interim data from a proof-of-concept study of its lead Cymerus MSC product, CYP-001, with the product demonstrating prolonged patient survival.
Plans for Phase 3 smoking cessation trial underway
04 April, 2016Invion has met with the US FDA to discuss Phase 3 plans for development of oral INV102 (nadolol) as a treatment for patients with chronic obstructive pulmonary disease (COPD) who cannot quit cigarette smoking.
Repairing blood vessels to improve anticancer treatment
01 April, 2016A new drug could be used to repair the blood vessel defects that prevent current anticancer treatments from entering tumours.
Wet AMD trial completes patient enrolment
30 March, 2016Opthea has completed patient enrolment in its ongoing phase 1 dose escalation clinical trial of OPT-302 as a novel therapy for wet age-related macular degeneration (wet AMD).
IDT's new manufacturing partner
30 March, 2016WellSpring Pharma Services has agreed to manufacture two to three pharmaceutical products that require manufacturing processes or scale not currently available at IDT's Boronia facilities.
Accelerating anticancer drug discovery
29 March, 2016MecRx has secured a $4 million investment from the Medical Research Commercialisation Fund to advance its breakthrough technology for accelerating drug discovery.
$1 million for radiopharma company
21 March, 2016Clarity Pharmaceuticals is one of 15 lucky companies that this month received grant funding through Accelerating Commercialisation.
Hydrogel to enable tumour-targeting cancer treatment
21 March, 2016Researchers have developed a 3D-printable material that opens the way to personalised cancer treatment by enabling multiple, simultaneous tests to find the correct therapy to target a particular tumour.
